Prescient Therapeutics Appoints Global Pharmaceutical Leader as New CEO

2 min read | December 17, 2024 01:42 PM AEDT | By Team Kalkine Media

Google News:

Prescient Therapeutics Appoints Global Pharmaceutical Leader as New CEO — Image source: shutterstock

Recent News

Could ASX Growth Stocks Be Set for the Next Market Shift?

Woolworths Climbs While Coles Skirts 52-Week Lows: The Supermarket Spl...

Retail Under Pressure: Why ASX Retail Stocks Face a Tougher Road Ahead

ASX Growth Stocks: Hidden Catalysts and Market Signals

Make Kalkine Media
My Trusted Source

Highlights

Prescient Therapeutics (PTX) names James McDonnell as its new CEO

McDonnell has extensive experience in global oncology and pharmaceutical sectors

The appointment is effective from January 20, 2025

Prescient Therapeutics (ASX:PTX), a clinical-stage oncology company developing targeted, personalised therapies for cancer, has announced the appointment of James McDonnell as its Chief Executive Officer, effective January 20, 2025. With more than two decades of experience in the global pharmaceutical industry, McDonnell is poised to bring strategic leadership to advance Prescient’s innovative cancer treatment pipeline.

McDonnell has built a distinguished career specialising in blood disorders and haematological malignancies, including myeloma and chronic myeloid leukaemia (CML). His expertise stems from leadership roles in key organisations such as Pharmion and CSL Vifor. At Pharmion, where he led Global Marketing, he was instrumental in strengthening the oncology and haematology portfolio, contributing to the company’s US$2.9 billion acquisition by Celgene Corporation (NASDAQ:CELG).

Following his success at Pharmion, McDonnell joined CSL Vifor, a renowned pharmaceutical company focused on areas such as patient blood management, nephrology, and rare diseases. As the global commercial lead, he played a significant role in driving enterprise-wide strategic initiatives and expanding global reach. Notably, during his tenure as Vice President and General Manager for CSL Vifor Australia and New Zealand, McDonnell’s leadership coincided with remarkable revenue growth across core portfolios.

A registered pharmacist and a member of the Royal Pharmaceutical Society, McDonnell’s academic background includes a Graduate Diploma in Marketing from Monash University and completion of the Australian Institute of Company Directors program. His combined scientific and business acumen positions him to lead Prescient Therapeutics through its next phase of growth and development.

Prescient Therapeutics (PTX) is at the forefront of oncology innovation, focusing on tailored treatments to address specific cancer types. The company’s pipeline includes therapies designed to improve outcomes for patients with complex and rare cancers. With McDonnell’s proven track record of delivering commercial success and fostering high-performing teams, the leadership shift aligns with Prescient’s mission to transform cancer treatment through personalised solutions.

As the company prepares for this strategic leadership transition, the appointment reflects its commitment to strengthening its position in the oncology sector while driving clinical advancements.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.